Trusted Resources: Education
Scientific literature and patient education texts
The First Mucopolysaccharidosis Type VII in a Taiwanese Girl: A Case Report and Review of the Literature
source: Journal of the Formosan Medical Association = Taiwan yi zhi
year: 2021
authors: Lee CL,Chuang CK,Hsu CH,Chiu HC,Tu RY,Lo YT,Chang YH,Lin HY,Lin SP
summary/abstract:The present study included the first case of mucopolysaccharidosis (MPS) type VII in Taiwan. During pregnancy, the patient was diagnosed with hydrops fetalis and had ascites aspiration 4 times. In the following years, she presented gradually with chronic lung disease, developmental delay, short stature, dysmorphic features of coarse face, macroglossia and pigeon chest with scoliosis. Upon referral at age 4 years, she had corneal clouding, mild limitation of range of motion (ROM) and hepatosplenomegaly. X-ray showed paddle ribs and dysplastic vertebral bodies. MPS was suspected and urine glycosaminoglycans (GAGs) elevated were noted. The leukocyte enzymatic analyses for MPS I, MPS II, MPS IIIB, MPS IVA, and MPS VI were all normal. Afterward, the molecular analysis showed two heterozygous genetic variants of c.104C > A and c.1454C > T in trans in the GUSB gene (NM_000181.4) which were the causes for MPS VII. Then, we checked the leukocyte β-glucuronidase activity for MPS VII and showed extremely low, therefore confirmed the diagnosis. Clinicians should increase the awareness on the early signs of MPS to have a prompt diagnosis and offer the correct treatment like enzyme replacement therapy (ERT) as early as possible.
organization: Department of Pediatrics, MacKay Memorial Hospital, Hsinchu, Taiwan; Institute of Clinical Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan; Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan; Department of Rare Disease Center, MacKay Memorial Hospital, Taipei, Taiwan; MacKay Junior College of Medicine, Nursing and Management, Taipei, Taiwan; Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.DOI: 10.1016/j.jfma.2021.07.024
read more
Related Content
-
New Type A ERT Candidate on Track for Clinical TrialJapanese company, JCR Pharmaceuticals, h...
-
Diagnosis of Mucopolysaccharidoses and Mucolipidosis by Assaying Multiplex Enzymes and GlycosaminoglycansMucopolysaccharidoses (MPS) and mucolipi...
-
Challenges of Enzyme Replacement Therapy for Sanfilippo SyndromeWhat Is Enzyme Replacement Therapy?Enzym...
-
What Is Sly Syndrome?https://www.youtube.com/watch?v=LwIHvN3G...
-
Enzyme Replacement Therapy With Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis o...Enzyme replacement therapy (ERT) improve...
-
Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment o...Denali Therapeutics Inc., a biopharmaceu...
-
[Pharmacological Property, Mechanism of Action and Clinical Study Results of Pabinafusp Alfa (Genetical Recombinatio...Mucopolysaccharidosis type II (MPS II) i...